SAB BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
SAB BIOTHERAPEUTICS, INC. (SABS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 17.26 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 8.41K shares, a 80.55% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 8.86K shares, a 25.56% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 45.40K shares, a 67.98% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 20.02K shares, a 65.68% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 120.55K shares, a 44.90% decline from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 218.76K shares, a 1358.23% increase from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 15.00K shares, a 1415.35% increase from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 990.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 8.41K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 17.26K shares 10-Q · filed 2026-08-06 | 62.66K shares derived: sum of 3 quarters · filed 2026-08-06 | 82.69K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 8.86K shares 10-Q · filed 2026-05-12 | 54.26K shares derived: sum of 2 quarters · filed 2026-05-12 | 74.28K shares derived: sum of 3 quarters · filed 2026-05-12 | 117.51K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 45.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 65.43K shares derived: sum of 2 quarters · filed 2026-03-09 | 108.65K shares derived: sum of 3 quarters · filed 2026-03-09 | 120.55K shares 10-K · filed 2026-03-09 |
| 2025-09-30 | 20.02K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 63.25K shares derived: sum of 2 quarters · filed 2025-11-14 | 75.15K shares 10-Q · filed 2025-11-14 | 216.96K shares derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | 43.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 55.12K shares 10-Q · filed 2025-08-07 | 196.94K shares derived: sum of 3 quarters · filed 2025-08-07 | 255.29K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 11.89K shares 10-Q · filed 2025-05-09 | 153.71K shares derived: sum of 2 quarters · filed 2025-05-09 | 212.06K shares derived: sum of 3 quarters · filed 2025-05-09 | 216.88K shares derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | 141.81K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 200.16K shares derived: sum of 2 quarters · filed 2025-03-31 | 204.99K shares derived: sum of 3 quarters · filed 2025-03-31 | 218.76K shares 10-K · filed 2025-03-31 |
| 2024-09-30 | 58.35K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 63.17K shares derived: sum of 2 quarters · filed 2024-11-06 | 76.95K shares 10-Q · filed 2024-11-06 | -45.62K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 4.82K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 18.60K shares 10-Q · filed 2024-08-08 | -103.97K shares derived: sum of 3 quarters · filed 2024-08-08 | 1.52K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 13.78K shares 10-Q · filed 2024-05-20 | -108.79K shares derived: sum of 2 quarters · filed 2024-05-20 | -3.30K shares derived: sum of 3 quarters · filed 2024-05-20 | 694.00 shares derived: sum of 4 quarters · filed 2024-05-20 |
| 2023-12-31 | -122.57K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -17.07K shares derived: sum of 2 quarters · filed 2024-03-29 | -13.08K shares derived: sum of 3 quarters · filed 2024-03-29 | 15.00K shares 10-K · filed 2024-03-29 |
| 2023-09-30 | 105.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 109.49K shares derived: sum of 2 quarters · filed 2023-11-13 | 137.57K shares 10-Q · filed 2023-11-13 | 137.57K shares derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | 3.99K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | 32.08K shares 10-Q · filed 2023-08-21 | 32.08K shares derived: sum of 3 quarters · filed 2023-08-21 | |
| 2023-03-31 | 28.09K shares 10-Q · filed 2023-05-15 | 28.09K shares derived: sum of 2 quarters · filed 2023-05-15 | ||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-14 | 990.00 shares 10-K · filed 2023-04-14 | ||
| 2022-09-30 | 990.00 shares 10-Q · filed 2022-11-14 | |||
| 2021-12-31 | 0.00 shares 10-K/A · filed 2023-04-28 | |||
| 2020-12-31 | 0.00 shares 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |